1. Scrip
  2. >>Business
  3. >>Earnings

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

 
• By Jessica Merrill

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

sunset golden crude pipelines in africa
Regeneron updated investors on its pipeline • Source: Shutterstock

Investors and the public are eagerly awaiting updates on Regeneron Pharmaceuticals, Inc.'s antibody cocktail for the treatment and prevention of SARS-Cov-2, but until data from ongoing late-stage clinical trials become available, developments on that front are largely wait-and-see.

During Regeneron's second quarter earnings call on 5 August, analysts pressed management for more details on the antibody cocktail REGN-COV2,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.